{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:39:45Z","timestamp":1791243585317,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.ejca.2010.02.026","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T02:10:16Z","timestamp":1269483016000},"page":"1223-1231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":326,"title":["Interleukin-6 in bone metastasis and cancer progression"],"prefix":"10.1016","volume":"46","author":[{"given":"Tasnim","family":"Ara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves A.","family":"DeClerck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.02.026_bib1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.02.026_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc865","article-title":"Dissemination and growth of cancer cells in metastatic sites","volume":"2","author":"Chambers","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2010.02.026_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1359\/jbmr.2003.18.2.190","article-title":"Mechanisms of tumor metastasis to the bone: challenges and opportunities","volume":"18","author":"Reddi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/1042819021000037985","article-title":"The regulation of hematopoietic stem cell and progenitor mobilization by chemokine SDF-1","volume":"44","author":"Hattori","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2010.02.026_bib5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2174\/1381612043452640","article-title":"Chemokines and their receptors as therapeutic targets: the role of the SDF-1\/CXCR4 axis","volume":"10","author":"Juarez","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejca.2010.02.026_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nri1779","article-title":"Bone-marrow haematopoietic-stem-cell niches","volume":"6","author":"Wilson","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2010.02.026_bib7","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.4049\/jimmunol.167.8.4747","article-title":"A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma","volume":"167","author":"Geminder","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2010.02.026_bib8","first-page":"1832","article-title":"Use of the stromal cell-derived factor-1\/CXCR4 pathway in prostate cancer metastasis to bone","volume":"62","author":"Taichman","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib9","first-page":"1","article-title":"The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma","author":"Strahm","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ejca.2010.02.026_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0889-8588(05)70413-5","article-title":"Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma","volume":"11","author":"Teoh","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejca.2010.02.026_bib11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/0008-5472.CAN-04-2853","article-title":"Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells","volume":"65","author":"Sohara","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/sj.bjc.6604238","article-title":"Interactions between microenvironment and cancer cells in two animal models of bone metastasis","volume":"98","author":"Blouin","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.02.026_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","article-title":"Crosstalk between cancer cells and bone microenvironment in bone metastasis","volume":"328","author":"Yoneda","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejca.2010.02.026_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00430-006-0019-9","article-title":"Interleukin-6 and its receptor: from bench to bedside","volume":"195","author":"Scheller","year":"2006","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.ejca.2010.02.026_bib15","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cncr.22999","article-title":"Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics","volume":"110","author":"Hong","year":"2007","journal-title":"Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.ejca.2010.02.026_bib16","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1186\/ar565","article-title":"The paradigm of IL-6: from basic science to medicine","volume":"4","author":"Naka","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib17","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.90100.2007","article-title":"Muscle as an endocrine organ: focus on muscle-derived interleukin-6","volume":"88","author":"Pedersen","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ejca.2010.02.026_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00011-009-0060-4","article-title":"The major inflammatory mediator interleukin-6 and obesity","volume":"58","author":"Eder","year":"2009","journal-title":"Inflamm Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","article-title":"Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis","volume":"71","author":"Howren","year":"2009","journal-title":"Psychosom Med"},{"key":"10.1016\/j.ejca.2010.02.026_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.3136546","article-title":"Cloning and expression of the human interleukin-6 (BSF-2\/IFN beta 2) receptor","volume":"241","author":"Yamasaki","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.ejca.2010.02.026_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1084\/jem.182.1.243","article-title":"Interleukin 6 is essential for in vivo development of B lineage neoplasms","volume":"182","author":"Hilbert","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2010.02.026_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.icb.7100113","article-title":"SIL-6R: more than an agonist?","volume":"86","author":"Knupfer","year":"2008","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.ejca.2010.02.026_bib23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0165-2478(99)00040-1","article-title":"Generation of \u2018truncated\u2019 interleukin-6 receptor (IL-6R) mRNA by alternative splicing; a possible source of soluble IL-6R","volume":"68","author":"Holub","year":"1999","journal-title":"Immunol Lett"},{"key":"10.1016\/j.ejca.2010.02.026_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0165-2478(96)02669-7","article-title":"The function of the soluble IL-6 receptor in vivo","volume":"54","author":"Peters","year":"1996","journal-title":"Immunol Lett"},{"key":"10.1016\/j.ejca.2010.02.026_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1189\/jlb.1105674","article-title":"Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer","volume":"80","author":"Rose-John","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ejca.2010.02.026_bib26","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood-2007-01-067918","article-title":"Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils","volume":"110","author":"Chalaris","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.02.026_bib27","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.4049\/jimmunol.180.11.7102","article-title":"Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells","volume":"180","author":"Briso","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2010.02.026_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-3083.2006.01750.x","article-title":"Interleukin-6 trans-signalling in chronic inflammation and cancer","volume":"63","author":"Scheller","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.ejca.2010.02.026_bib29","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/art.21818","article-title":"Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis","volume":"54","author":"Richards","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejca.2010.02.026_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.ejca.2010.02.026_bib31","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2010.02.026_bib32","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2002-08-2640","article-title":"Downstream effectors of oncogenic ras in multiple myeloma cells","volume":"101","author":"Hu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.02.026_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-3-1","article-title":"PI3-K\/Akt pathway contributes to IL-6-dependent growth of 7TD1 cells","volume":"3","author":"Zhang","year":"2003","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ejca.2010.02.026_bib34","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.0022-202X.2004.23497.x","article-title":"Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK\/STAT3 and PI3-kinase\/Akt pathways","volume":"123","author":"Jee","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2010.02.026_bib35","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/en.2004-1167","article-title":"Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin\/receptor activator of nuclear factor-{kappa}B (RANK) ligand\/RANK system","volume":"146","author":"Liu","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejca.2010.02.026_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/0008-5472.CAN-08-0613","article-title":"Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells","volume":"69","author":"Ara","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10555-006-9022-2","article-title":"The role of Wnts in bone metastases","volume":"25","author":"Hall","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ejca.2010.02.026_bib38","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.ejca.2010.02.026_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Kang","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2010.02.026_bib40","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/01.blo.0000093055.96273.69","article-title":"Transforming growth factor-beta in osteolytic breast cancer bone metastases","author":"Guise","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0014-5793(01)02258-X","article-title":"Cross-talk between IL-6 and TGF-beta signaling in hepatoma cells","volume":"492","author":"Yamamoto","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ejca.2010.02.026_bib42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2009.02.015","article-title":"Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors","volume":"15","author":"Lee","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2010.02.026_bib43","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1128\/MCB.25.17.7432-7440.2005","article-title":"Role of Stat3 in regulating p53 expression and function","volume":"25","author":"Niu","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejca.2010.02.026_bib44","first-page":"6659","article-title":"Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells","volume":"62","author":"Mora","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2010.02.026_bib46","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1200\/JCO.2005.05.024","article-title":"Identification and validation of novel therapeutic targets for multiple myeloma","volume":"23","author":"Hideshima","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.02.026_bib47","doi-asserted-by":"crossref","first-page":"18573","DOI":"10.1074\/jbc.M803115200","article-title":"Identification of Gal-3 binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma","volume":"27","author":"Fukaya","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2010.02.026_bib48","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.159.5.2212","article-title":"IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade","volume":"159","author":"Ogata","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2010.02.026_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1359-6101(00)00021-6","article-title":"Interleukin-6 and prostate cancer progression","volume":"12","author":"Smith","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ejca.2010.02.026_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2009.01.002","article-title":"Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis","volume":"15","author":"Bollrath","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2010.02.026_bib51","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/sj.onc.1205859","article-title":"Roles of activated Src and Stat3 signaling in melanoma tumor cell growth","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2010.02.026_bib52","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)64278-2","article-title":"Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events","volume":"162","author":"Quintanilla-Martinez","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2010.02.026_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","article-title":"Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells","volume":"12","author":"Gritsko","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.molmed.2006.11.001","article-title":"The STAT3 oncogene as a predictive marker of drug resistance","volume":"13","author":"Barre","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ejca.2010.02.026_bib55","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-08-2419","article-title":"Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation","volume":"69","author":"Shain","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cytogfr.2008.11.004","article-title":"The dual role of IL-6-type cytokines on bone remodeling and bone tumors","volume":"20","author":"Blanchard","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ejca.2010.02.026_bib57","doi-asserted-by":"crossref","first-page":"19301","DOI":"10.1074\/jbc.274.27.19301","volume":"274","author":"O\u2019Brien","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2010.02.026_bib58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00223-004-0113-1","article-title":"The interleukin-6\/soluble interleukin-6 receptor system induces parathyroid hormone-related protein in human osteoblastic cells","volume":"75","author":"Guillen","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ejca.2010.02.026_bib59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/excr.2002.5627","article-title":"Gp130 activation by soluble interleukin-6 receptor\/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells","volume":"280","author":"Erices","year":"2002","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib60","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.4049\/jimmunol.178.9.5588","article-title":"Protein inhibitor of activated STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and osteoclast-associated receptor","volume":"178","author":"Kim","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2010.02.026_bib61","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ejca.2005.12.026","article-title":"Signalling and survival pathways in multiple myeloma","volume":"42","author":"Bommert","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.02.026_bib62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bone.2006.02.074","article-title":"A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation","volume":"39","author":"Itoh","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.ejca.2010.02.026_bib63","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1074\/jbc.M110773200","article-title":"JAK\/STAT but not ERK1\/ERK2 pathway mediates interleukin (IL)-6\/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression","volume":"278","author":"Legendre","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2010.02.026_bib64","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1158\/0008-5472.CAN-05-2674","article-title":"Activation of stat3 in human melanoma promotes brain metastasis","volume":"66","author":"Xie","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib65","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2010.02.026_bib66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.jcbfm.9600509","article-title":"Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro","volume":"28","author":"Fan","year":"2008","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.ejca.2010.02.026_bib67","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1172\/JCI35213","article-title":"Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice","volume":"118","author":"Kujawski","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2010.02.026_bib68","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/sj.onc.1206226","article-title":"Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway","volume":"22","author":"Wei","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2010.02.026_bib69","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor\u2013stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.02.026_bib70","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF02256101","article-title":"Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma","volume":"11","author":"Huang","year":"2004","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.ejca.2010.02.026_bib71","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2010.02.026_bib72","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2010.02.026_bib73","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.1158\/1078-0432.CCR-07-5017","article-title":"Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma","volume":"14","author":"Egler","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib74","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0753-3322(01)00079-8","article-title":"Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients","volume":"55","author":"Kovacs","year":"2001","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejca.2010.02.026_bib75","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/09629359990289","article-title":"Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission","volume":"8","author":"Robak","year":"1999","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ejca.2010.02.026_bib76","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1860::AID-CNCR7>3.0.CO;2-R","article-title":"The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma","volume":"82","author":"Stasi","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.02.026_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-4804(01)96222-5","article-title":"Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation?","volume":"107","author":"Dowdall","year":"2002","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1096\/fj.99-1003rev","article-title":"The soluble interleukin 6 receptor: mechanisms of production and implications in disease","volume":"15","author":"Jones","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.ejca.2010.02.026_bib79","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ijc.20270","article-title":"CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice","volume":"111","author":"Zaki","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.02.026_bib80","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1158\/1078-0432.CCR-07-1293","article-title":"Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma","volume":"13","author":"Voorhees","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib81","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2009.07647.x","article-title":"Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death","volume":"145","author":"Voorhees","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2010.02.026_bib82","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2141.2000.02093.x","article-title":"A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma","volume":"109","author":"Moreau","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2010.02.026_bib83","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejca.2010.02.026_bib84","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.02.026_bib85","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejca.2010.02.026_bib86","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.02.026_bib87","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejca.2010.02.026_bib88","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1196\/annals.1378.063","article-title":"Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution","volume":"1091","author":"Aggarwal","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejca.2010.02.026_bib89","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-08-0149","article-title":"Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo","volume":"8","author":"Burger","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.02.026_bib90","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1073\/pnas.0609757104","article-title":"Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity","volume":"104","author":"Siddiquee","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2010.02.026_bib91","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/onc.2008.448","article-title":"The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling","volume":"28","author":"Lin","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2010.02.026_bib92","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1535-7163.MCT-08-0138","article-title":"Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas","volume":"7","author":"Yang","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.02.026_bib93","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2010.02.026_bib94","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1634\/theoncologist.12-2-191","article-title":"Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer","volume":"12","author":"Gridelli","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2010.02.026_bib95","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","article-title":"Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells","volume":"69","author":"Xin","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib96","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/JCO.2008.19.0108","article-title":"Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma","volume":"27","author":"Feldman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.02.026_bib97","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1586\/14737140.6.8.1165","article-title":"Lenalidomide in multiple myeloma","volume":"6","author":"Richardson","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2010.02.026_bib98","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","article-title":"The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions","volume":"77","author":"Lu","year":"2009","journal-title":"Microvasc Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib99","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.02.026_bib100","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.ju.0000070685.34760.5f","article-title":"Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells","volume":"170","author":"Oades","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2010.02.026_bib101","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2165\/00003495-200464110-00004","article-title":"Zoledronic acid: a review of its use in patients with advanced cancer","volume":"64","author":"Perry","year":"2004","journal-title":"Drugs"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2010.02.026_bib102","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2010.02.026_bib103","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.02.026_bib104","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491000153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491000153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:17:15Z","timestamp":1760732235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491000153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":104,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S095980491000153X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.02.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-6 in bone metastasis and cancer progression","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2010.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}